Lupin launches tablets in US to treat infections
PTI|
Updated: Nov 02, 2017, 10.09 PM IST
NEW DELHI: Drug firm Lupin today said it has launched in the American market Doxycycline Hyclate tablets USP, used for treating various infections.
The 75 mg and 150 mg tablets were launched after receiving the approval for the from the United States Food and Drug Administration (USFDA), Lupin said in a filing to BSE.
They are generic versions of Aqua Pharmaceuticals, LLC's Acticlate tablets in the same strengths, it added.
"They are indicated in the treatment of infections caused by various micro-organisms and as an adjunctive therapy in severe acne," Lupin said.
As per the IMS MAT June 2017 data the tablets had annual sales of approximately USD 263 million in the US, it added.
Shares of Lupin Ltd rose 3.26 per cent to Rs 1,060.90 on BSE.
The 75 mg and 150 mg tablets were launched after receiving the approval for the from the United States Food and Drug Administration (USFDA), Lupin said in a filing to BSE.
They are generic versions of Aqua Pharmaceuticals, LLC's Acticlate tablets in the same strengths, it added.
"They are indicated in the treatment of infections caused by various micro-organisms and as an adjunctive therapy in severe acne," Lupin said.
As per the IMS MAT June 2017 data the tablets had annual sales of approximately USD 263 million in the US, it added.
Shares of Lupin Ltd rose 3.26 per cent to Rs 1,060.90 on BSE.
